Please assess the completion status of the following clinical trial:

Trial Title: Imiquimod Treatment of CIN Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* newly diagnosed high grade CIN lesions (CIN 2-3), histologically confirmed~* age 18 years or older~Exclusion criteria:~* immunodeficiency~* pregnancy or lactation~* legally incapability~* history of histologically conformed high-grade CIN

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Imiquimod treatment arm (Type: EXPERIMENTAL): Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
- Standard treatment arm (Type: ACTIVE_COMPARATOR): Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).